Shortened Exclusivity Could Save $31B

Alex Brill was recently quoted by Politico Pro about MGA’s recent “Gamesmanship and Other Barriers to Drug Competition” paper:

“Brand-name medicines’ market exclusivity periods have climbed an average of 2.2 years since the mid-1990s, steadily delaying the market arrival of generic rivals. Reversing that trend alone could save the U.S. health care system roughly $31.7 billion, according to a Matrix report commissioned by the Coalition for Affordable Prescription Drugs, a group of insurers, pharmacy benefit managers and large employers.

Tactics ranging from patent thickets to citizens’ petitions and authorized generics — identical drugs produced or authorized by the brand-name company — have been some of the most effective ways to delay market competition, Matrix’s Alex Brill writes.”

Read Here (Subscription Required)